目的评价立体定向放射治疗联合厄洛替尼治疗晚期非小细胞肺癌的疗效和不良反应。方法42例晚期非小细胞肺癌患者均经病理组织学或细胞学检查确诊。所有病例于2008-08至2012-08均行伽马刀治疗后，开始口服靶向药物厄洛替尼，100～150mg/d，进食1h前或进食2h后服药;连续不间断服药至少2个月。伽马刀治疗结束至少1个月后评价疗效及不良反应。结果全组42例患者客观有效率(responserate，RR)19.9%(8/42)，疾病控制率(diseasecontrolrate，DCR)61.9%(26/42);中位疾病进展时间(themediantimetodiseaseprogression，TTP)5.2个月，中位生存期(mediansurvivaltime，MST)11.5个月。不良反应多为Ⅰ/Ⅱ度，Ⅲ/Ⅳ度较少。结论采用γ-立体定向放疗结合靶向药物厄洛替尼对晚期非小细胞肺-癌进行治疗效果较好，不良反应轻微，多数患者能耐受治疗。
Abstract
Objective To evaluate the efficacy and adverse effects of γ-SBRT combinaed with targeted drug erlotinib on advanced stage non-small cell lung cancer. Methods Forty-two advanced stage non-small cell lung cancer patients were finally confirmed by pathohistological or cytological examination. All patients, after starting gamma knife radiosurgery, took orally targeted drugs erlotinib from August 2008 to August 2012,100-150 mg/d,1 hour before meal eating or 2 hours after meal, uninterrupted medication for at least 2 months. The efficacy and toxic reactions were evaluated after at least one month at the end of gamma knife radiosurgery. Results In 42 patients, the objective response rate reached 19.0%(8/42), the disease control rate reached 61.9% (26/42) , and the median time to disease progression was 5.2 months, the median survival time was 11.5 months. Major adverse effects were myelosuppression, lassitude and gastrointestinal tract reactions, most of which wereⅠ/Ⅱ degree with less being Ⅲ/Ⅳ degree. Conclusions The efficacy of γ-SBRT in combined with targeted drug erlotinib on advanced stage non-small cell lung cancer is acceptable and adverse effects are tolerable.
关键词
非小细胞肺癌 /
立体定向放射治疗 /
靶向治疗 /
厄洛替尼
Key words
non-small cell lung cancer /
stereotactic radiation therapy /
targeted therapy /
erlotinib
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] 郑爱青,郑 培,于金明,等. 吉西他滨单药或联合卡铂治疗老年晚期非小细胞肺癌疗效观察[J]. 武警医学,2011,22(6): 501-504.
[2] Timmerman R D, Kavanagh B D. Stereotatic body radiation therapy[J]. Curr probl Cancer, 2005, 29(3): 120-157.
[3] Martel M K. Advanced radiation treatment planning and delivery approaches for treatment of lung cancer[J]. Hematol Oncol Clin North Am, 2004, 18(1): 231-43.
[4] 卢 飞,赵品婷,姚红军,等. 全身伽玛刀同步辅助化疗治疗局部晚期非小细胞肺癌的疗效观察[J]. 现代肿瘤医学,2008,16(8):1317-1318.
[5] 周 翔,许亚萍,马胜林,等. 吉非替尼对肺癌A549细胞系的放射增敏作用[J]. 临床肿瘤学杂志,2007,12(11):814-821.
[6] von Pawel J, Wagner H, Duell T, et al. Erlotinib in patients with previously irradiated, recurrent brain metastases from non-small cell lung cancer: two case reports. Onkologie[J], 2008, 31(3):123-126.
[7] Lind J S, Lagerwaard F J, Smit E F, et al. Phase I study of concurrent whole brain radiotherapy and erlotinib for multiple brain metastases from non-small-cell lung cancer[J]. Int J Radiat Oncol Biol Phys, 2009, 74(5):1391-1396.
[8] 赵 荆,付 强,张莉红. 厄洛替尼联合全脑放疗治疗非小细胞肺癌脑转移的临床观察[J]. 中国肺癌杂志,2009,12(12):1291-1294.
[9] Wang M, Morsbach F, Sander D, et al. EGF receptor inhibition radiosensitizes NSCLC cells by inducing senescence in cells sustaining DNA double-strand breaks[J]. Cancer Res, 2011, 71(19):6261-6269.
[10] Perez-Soler R, Chachoua A, H ammond L A, et al.Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer[J]. J Clin Oncol,2004,22(16):3238-3247.
PDF(579 KB)
